Healthcare

Editas Medicine reports Q4 loss of $0.06/share, narrower than the $0.21 consensus estimate.

Financial Performance and Liquidity Revenues for the fourth quarter of 2025 reached $30.3 million, an increase from $21.2 million in…

Biopharmaceutical company CorMedix Inc. (NASDAQ: CRMD) reported a sharp increase in revenues for the fourth quarter of fiscal 2025, primarily…

Biopharmaceutical company Liquidia Corporation (NASDAQ: LQDA) reported a profit for the fourth quarter of fiscal 2025, compared to a loss…

EyePoint, Inc. (NASDAQ: EYPT), which is engaged in the development of therapeutics for retinal diseases, on Wednesday announced financial results…

Optical retail company National Vision Holdings, Inc. (NASDAQ: EYE) on Wednesday announced financial results for the fourth quarter of FY25,…

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a biopharmaceutical company engaged in the discovery and development of cancer drugs, reported a narrower…

Ticker: CYRX | Exchange: NASDAQ | Report Date: March 3, 2026, after market close Cryoport, the specialized cold chain logistics…

Ticker: RIGL | Exchange: NASDAQ | Report Date: March 3, 2026, after market close Rigel Pharmaceuticals, a specialty pharma company…

Zymeworks Inc. (NASDAQ: ZYME), a Canada-based clinical-stage biotechnology company, on Monday reported a wider net loss for the fourth quarter…